Corporate
Profile

Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.
See Japanese corporate profile

Latest update： 09/11/2020 15:00:00

Oncolys BioPharma Inc. 

Drug discovery based on virology

We aim to be the only drug discovery venture business in Japan that uses technology based on virology to develop new drugs for cancer and infectious diseases. As we promote development in the study of cancer and serious infectious diseases with our drug candidates Telomelysin® and OBP-601 (Censavudine), we are building a pipeline that encompasses early cancer detection, localized treatment of cancer in the early stages, post-operative examination, and metastatic cancer treatment by preparing Telomelysin, a new diagnostic agent to detect early stages of cancer, and conducting post-operative examinations, and conducting research into OBP-801, a new epigenetic cancer treatment.

Inquiry
Main image

This company is recommended by the following support organizations.

Marketing Support Department, SMRJ
Inquiry

Similar Companies

Global PS Inc.
Our company conducts international sales of label printers that enable one-pass operation of GHS label printing in two colors (red and black). A near-edge head is installed in these printers. Wide labels with a width up to eight inches can be used. A high-speed rotary type single blade cutter is available as an option.
総合サービス株式会社
FPEC Corporation
We have extensive experience and knowledge in the basic design of plant disaster prevention systems and provide practical and effective services with an engineering approach. We have developed a number of simulation software programs for leakage and diffusion of hazardous materials, explosions, fires, etc., and provide solutions to many customers using these tools. In recent years, we have been expanding our business to meet the needs of various fields such as electronics, chemicals, construction, laboratories, and cultural assets.